Skip to main content

Advertisement

SpringerLink
Log in

Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis

  • Original Research
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Tumor necrosis factor α inhibitors (TNFi) are the major class of biologic drug used for the treatment of Rheumatoid arthritis (RA). Their effects on inflammation and disease control are well established, but this is not true also for bone metabolism, especially for key factors as parathyroid hormone and Wnt pathway. Those two pathways are gaining importance in the pathogenesis RA bone damage, both systemic and local, but how the new treatment affects them is still largely unknown. We studied 54 RA patients who were starting an anti-TNFα treatment due to the failure of the conventional synthetic disease-modifying antirheumatic drugs. Serum levels of Wnt/βcatenin pathway inhibitors (Dickkopf-related protein 1, Dkk1, and Sclerostin), Parathyroid hormone (PTH), vitamin D, and bone turnover markers were measured at baseline in the morning after fasting and after 6 months of therapy. We found a significant percentage increase in serum PTH (+32 ± 55 %; p = 0.002) and a decrease in Dkk1 mean serum levels (−2.9 ± 12.1; p = 0.05). PTH percentage changes were positively correlated both with C-terminal telopeptide of type I collagen and Dkk1 percentage changes. Sclerostin serum levels showed no significant difference. TNFi treatment provokes in the short term a rise in PTH levels and a decrease in Dkk1 serum levels. The increase of PTH might promote bone resorption and blunt the normalization of Dkk1 serum levels in RA. Those data give a new insight into TNFi metabolic effects on bone and suggest new strategies to achieve better results in terms of prevention of bone erosions and osteoporosis with TNFi treatment in RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gravallese EM (2002) Bone destruction in arthritis. Ann Rheum Dis 61:84–86

    Article  Google Scholar 

  2. Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8:656–664. doi:10.1038/nrrheum.2012.153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Scott DL, Wolfe F, Huizinga TWJ (2010) Rheumatoid arthritis. Lancet Lond Engl 376:1094–1108. doi:10.1016/S0140-6736(10)60826-4

    Google Scholar 

  4. Roux S, Orcel P (2000) Bone loss. Factors that regulate osteoclast differentiation: an update. Arthritis Res 2:451–456. doi:10.1186/ar127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jilani AA, Mackworth-Young CG (2015) The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis. Int J Rheumatol 2015:728610. doi:10.1155/2015/728610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Diarra D, Stolina M, Polzer K et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163. doi:10.1038/nm1538

    Article  CAS  PubMed  Google Scholar 

  7. Rossini M, Gatti D, Adami S (2013) Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121–132. doi:10.1007/s00223-013-9749-z

    Article  CAS  PubMed  Google Scholar 

  8. Wang S-Y, Liu Y-Y, Ye H et al (2011) Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 38:821–827. doi:10.3899/jrheum.100089

    Article  CAS  PubMed  Google Scholar 

  9. Rossini M, Viapiana O, Adami S et al (2015) In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol 33:77–83

    PubMed  Google Scholar 

  10. Heiland GR, Zwerina K, Baum W et al (2010) Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 69:2152–2159. doi:10.1136/ard.2010.132852

    Article  CAS  PubMed  Google Scholar 

  11. Kotake S, Nanke Y (2014) Effect of TNFα on osteoblastogenesis from mesenchymal stem cells. Biochim Biophys Acta 1840:1209–1213. doi:10.1016/j.bbagen.2013.12.013

    Article  CAS  PubMed  Google Scholar 

  12. Adamopoulos IE, Mellins ED (2015) Alternative pathways of osteoclastogenesis in inflammatory arthritis. Nat Rev Rheumatol 11:189–194. doi:10.1038/nrrheum.2014.198

    Article  CAS  PubMed  Google Scholar 

  13. Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588. doi:10.1136/ard.2010.138461

    Article  PubMed  Google Scholar 

  14. Prevoo ML, van ’t Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    Article  CAS  PubMed  Google Scholar 

  15. Orsolini G, Adami G, Adami S et al (2016) Short-term effects of TNF inhibitors on bone turnover markers and bone mineral density in rheumatoid arthritis. Calcif Tissue Int. doi:10.1007/s00223-016-0114-x

    Google Scholar 

  16. Szentpetery A, McKenna MJ, Murray BF et al (2013) Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis. J Rheumatol 40:653–662. doi:10.3899/jrheum.120397

    Article  CAS  PubMed  Google Scholar 

  17. Vis M, Havaardsholm EA, Haugeberg G et al (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499. doi:10.1136/ard.2005.044198

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lim MJ, Kwon SR, Joo K et al (2014) Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use. Kor J Intern Med 29:807–813. doi:10.3904/kjim.2014.29.6.807

    Article  Google Scholar 

  19. Manara M, Sinigaglia L (2015) Bone and TNF in rheumatoid arthritis: clinical implications. RMD Open 1:e000065. doi:10.1136/rmdopen-2015-000065

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501. doi:10.1210/edrv.22.4.0437

    Article  CAS  PubMed  Google Scholar 

  21. Augustine MV, Leonard MB, Thayu M et al (2014) Changes in vitamin D-related mineral metabolism after induction with anti-tumor necrosis factor-α therapy in Crohn’s disease. J Clin Endocrinol Metab 99:E991–E998. doi:10.1210/jc.2013-3846

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Pacifici R (2013) Role of T cells in the modulation of PTH action: physiological and clinical significance. Endocrine 44:576–582. doi:10.1007/s12020-013-9960-8

    Article  CAS  PubMed  Google Scholar 

  23. Tawfeek H, Bedi B, Li J-Y et al (2010) Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PloS One 5:e12290. doi:10.1371/journal.pone.0012290

    Article  PubMed  PubMed Central  Google Scholar 

  24. Viapiana O, Fracassi E, Troplini S et al (2013) Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int 92:324–329. doi:10.1007/s00223-012-9665-7

    Article  CAS  PubMed  Google Scholar 

  25. Gatti D, Viapiana O, Idolazzi L et al (2011) The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96:1555–1559. doi:10.1210/jc.2010-2552

    Article  CAS  PubMed  Google Scholar 

  26. Borggrefe J, Graeff C, Nickelsen TN et al (2010) Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 25:472–481. doi:10.1359/jbmr.090820

    Article  CAS  Google Scholar 

  27. Garnero P, Tabassi NC-B, Voorzanger-Rousselot N (2008) Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 35:2313–2315

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was performed in part in the LURM (Laboratorio Universitario di Ricerca Medica) Research Center, the University of Verona. The authors would like to thank Prof. Silvano Adami who left us the love for research and truth and the laboratory teams, especially Caterina Fraccarollo, for performing the biochemical analyses

Author information

Authors and Affiliations

  1. Rheumatology Section, Department of Medicine, University of Verona, Policlinico G.B Rossi, Piazzale Ludovico Scuro, 10, 37134, Verona, Italy

    Giovanni Adami, Giovanni Orsolini, Silvano Adami, Ombretta Viapiana, Luca Idolazzi, Davide Gatti & Maurizio Rossini

Authors
  1. Giovanni Adami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Orsolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silvano Adami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ombretta Viapiana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luca Idolazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Davide Gatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maurizio Rossini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Adami.

Ethics declarations

Conflict of Interest

Adami Giovanni, Orsolini Giovanni, Adami Silvano, Viapiana Ombretta, Idolazzi Luca, Gatti Davide, and Rossini Maurizio have no conflict of interest to declare.

Human and Animal Rights and Informed Consent

The study was approved by the institutional review board of the Medical School of Verona and performed according to the Helsinki declaration. All patients provided written informed consent for their participation in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adami, G., Orsolini, G., Adami, S. et al. Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis. Calcif Tissue Int 99, 360–364 (2016). https://doi.org/10.1007/s00223-016-0161-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-016-0161-3

Keywords

Search

Navigation